Other grades of this product :
| p38 MAP Kinase Inhibitor III Basic information |
| Product Name: | p38 MAP Kinase Inhibitor III | | Synonyms: | p38 MAP Kinase Inhibitor III - CAS 581098-48-8 - Calbiochem;(S)-p38 MAPK Inhibitor III;2-Pyridinamine, 4-[5-(4-fluorophenyl)-2-(methylthio)-1H-imidazol-4-yl]-N-[(1S)-1-phenylethyl]-;(S)-p38 MAP Kinase Inhibitor III | | CAS: | 581098-48-8 | | MF: | C23H21FN4S | | MW: | 404.5 | | EINECS: | | Product Categories: | | Mol File: | 581098-48-8.mol |
| p38 MAP Kinase Inhibitor III Chemical Properties |
| Melting point | 117-119 °C | | Boiling point | 589.4±60.0 °C(Predicted) | | density | 1.30±0.1 g/cm3(Predicted) | | storage temp. | +2C to +8C | | form | Yellow solid | | pka | 9.07±0.10(Predicted) |
| p38 MAP Kinase Inhibitor III Usage And Synthesis |
| Description | (S)-p38 MAPK inhibitor III is a methylsulfanylimidazole that inhibits p38 MAP kinase (IC50 = 0.90 μM in vitro). It is cell-permeable, potently blocking the release of TNF-α and IL-1β from human peripheral blood mononuclear cells (IC50s = 0.37 and 0.044 μM, respectively). | | General Description | A cell-permeable methylsulfanylimidazole compound that acts as a potent, selective, reversible, and ATP-competitive p38 MAP kinase inhibitor (IC50 = 0.38 μM for p38α). Shown to effectively suppresses LPS-induced cytokine release both in vitro (IC50 = 0.16 and 0.039 μM for TNF-α and IL-1β release, respectively, in human PBMC) and in vivo (ED50 = 1.33 mg/kg for TNF-α release in mouse). When compared with SB 203580 (Cat. No. 559389 and 559398), it exhibits reduced inhibitory activity against cytochrome P450-2D6 isoform and, therefore, is better suited for in vivo use. A 10 mM (1 mg/247 μl) solution of p38 MAP Kinase Inhibitor III (Cat. No. 506148) in DMSO is also available. | | Biochem/physiol Actions | Cell permeable: yes |
| p38 MAP Kinase Inhibitor III Preparation Products And Raw materials |
|
日本语
한국어
Français
Deutsch
España
Türkiye